Recent Updates — VRAX
Virax Biolabs Group Limited announced the appointment of AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. as non-exclusive distributors for its ImmuneSelect research-use immune profiling products in mainland China. The agreements expand distribution routes to key biotech centers including Beijing, Shanghai, Suzhou, and Wuhan, targeting academic, industrial, and biopharmaceutical customers across six provinces. This strategy supports commercial expansion while maintaining a capital-efficient model by leveraging established local networks rather than building a direct sales force. Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling.
Virax Biolabs Group Limited is restructuring its senior management to streamline operations and reduce costs while prioritizing ViraxImmune development. The company eliminated the standalone Chief Operating Officer position, making Dr. Nigel McCracken's role redundant. He enters paid garden leave on October 5, 2026, with employment terminating December 23, 2026; he will remain a board director and receive statutory redundancy plus payment in lieu of notice. The Board appointed Clement Monteil as Acting Chief Scientific Officer for six months effective immediately. Dr. Monteil has served as Head of R&D since 2022. Virax Biolabs Group Limited operates in the biotechnology sector, focusing on vaccine development and manufacturing.
Virax Biolabs Group Limited filed a Sticker Prospectus Supplement to increase the maximum aggregate offering amount of Ordinary Shares available for sale under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The new limit is set at $2,070,060.20, which excludes $3,658,152 of shares previously sold under the program. This amendment supplements the original agreement dated January 22, 2024, and related prospectus supplements from December 2023 and September 2024. The filing includes a legal opinion regarding the legality of the issuance. Virax Biolabs Group Limited operates in the biotechnology industry, specializing in viral vector manufacturing for gene therapy and vaccine development.
Virax Biolabs Group Limited convened an Extraordinary General Meeting on August 14, 2026, which lacked a quorum and was adjourned to August 21. At the reconvened meeting, shareholders approved by ordinary resolution an increase in authorized share capital from US$50,000 (2 million shares) to US$12,500,000 (500 million shares), creating 498 million new ordinary shares with a par value of US$0.025 each. However, shareholders rejected the special resolution required to adopt the fifth amended and restated memorandum and articles of association intended to reflect this revised capital structure. Virax Biolabs Group Limited operates in the biotechnology industry, specializing in viral vector manufacturing for gene therapy and vaccine development.
Virax Biolabs Group Limited is holding an Extraordinary General Meeting on August 14, 2026, to seek shareholder approval for increasing its authorized share capital from US$50,000 (2 million shares) to US$12.5 million (500 million shares). This creation of 498 million new ordinary shares is intended to provide funding and transactional flexibility for operations and business development related to ViraxImmune™. The company will also adopt a Fifth Amended and Restated Memorandum and Articles of Association to reflect this capital increase. Virax Biolabs Group Limited operates in the biotechnology industry, focusing on viral vector manufacturing and vaccine development.